Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of HLX10 plus carboplatin-etoposide in previously untreated extensive-stage small cell lung cancer
CTR20190754Phase 3Completed
- Sponsor
- HyBioPharma
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in small cell lung cancer (SCLC), sponsored by HyBioPharma. Started Sep 2019; status: completed.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20190754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190754.